The Age of Personalized Medicine Blog
Experts discuss the latest science and policy issues in personalized medicine
RSS
-
Join 201 other subscribers
@AgeofPM on Twitter
- RT @theMMRF: .@KathyGiusti shares thoughts on @WhiteHouse #PrecisionMedicine Initiative & what means 4 ur health for.tn/1Keu1jS @Fo… 8 years ago
- .@NIHDirector Oncology is clear choice for enhancing near-term impact of #PrecisionMedicine. More in @NEJM, bit.ly/1wIGW6e #T3Cancer 8 years ago
About
Contributors
- Adam Clark, FasterCures
- Amy Abernethy, Duke Comprehensive Cancer Center
- Amy M. Miller, PMC
- Audrey Gordon, Progeria Research Foundation
- Christopher-Paul Milne, Tufts CSDD
- Darrell West, Brookings Institution
- David Parker, Boston Healthcare Associates
- Donna Cryer, CryerHealth
- Edward Abrahams, PMC
- Geoff Ginsburg, Duke IGSP
- Ger Brophy, GE Healthcare Medical Diagnostics
- Gregory Downing, Personalized Health Care Initiative
- J. Leonard Lichtenfeld, American Cancer Society
- Jennifer Giordano-Coltart, Kilpatrick Townsend
- Jennifer Leib, CRD Associates
- Jerry Coamey, CAHG
- John J. Castellani, PhRMA
- John Lauerman, Bloomberg News
- Jon Retzlaff, AACR
- Kate Connors, PhRMA
- Kelly Lindenboom, Verenium Corporation
- Kevin Davies, Author, The $1,000 Genome
- Kristin Ciriello Pothier, Health Advances
- Lawrence J. Lesko, University of Florida College of Pharmacy
- Leslie Gordon, Progeria Research Foundation
- Marcia Kean, Feinstein Kean Healthcare
- Margaret Foti, AACR
- Michael Christman, Coriell Institute for Medical Research
- Michael Kolodziej, Aetna
- Peter Neupert, Microsoft Health Solutions Group
- Raju Kucherlapati, Harvard Medical School
- Ralph Snyderman, Duke University
- Randy Burkholder, PhRMA
- Richard Katz, GWU Hospital
- Richard Meyer, Kilpatrick Townsend
- Sheila Walcoff, McDermott, Will & Emery, LLP
- Stacie Propst, Research!America
- Stephanie Dunn Haney, Patient Advocate
- Stephen Eck, Astellas Pharma Global Development
- Thomas Goetz, WIRED
- Thomas Goss, Boston Healthcare Associates
- Tiffany Harrington, PMC
- Timothy Swope, PMC
- Tony Coelho, PIPC
- Werner Verbiest, Johnson and Johnson
- William Chin, PhRMA
- William Dalton, Moffitt Cancer Center
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- April 2014
- March 2014
- January 2014
- December 2013
- November 2013
- October 2013
- August 2013
- July 2013
- May 2013
- April 2013
- March 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- January 2012
- December 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
Categories
- ASCO
- Biomarker research
- cancer
- cardiovascular disease
- Clinical trials
- CMS
- comparative effectiveness research
- Diagnostics
- Drug development
- FDA
- genetic testing
- genomics
- Genomics and Personalized Medicine Act
- GTR
- Health care reform
- health cost containment
- Health information technology
- Human Genome Project
- Innovation
- Next-generation sequencing
- NIH
- Oncology
- Partnerships
- Patient Impact
- PCORI
- Personalized health care
- Personalized Medicine Coalition
- Personalized Medicine Conference
- Pharmaceutical Company Investment
- Pharmaceutical investment
- Policy Issues
- Progeria
- Provider education
- Rare disease
- regulation
- Reimbursement
- SACGHS
- Strategic Partnerships
- targeted therapies
- Translational research
- Turning the Tide Against Cancer
- Uncategorized
- Value
The Age of Personalized Medicine Blog 